+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Male Hypogonadism - Global Market Trajectory & Analytics

  • ID: 5309786
  • Report
  • April 2021
  • Region: Global
  • 182 pages
  • Global Industry Analysts, Inc
Global Male Hypogonadism Market to Reach $3.5 Billion by 2027

Amid the COVID-19 crisis, the global market for Male Hypogonadism estimated at US$2.8 Billion in the year 2020, is projected to reach a revised size of US$3.5 Billion by 2027, growing at a CAGR of 2.9% over the period 2020-2027. Testosterone Replacement Therapy, one of the segments analyzed in the report, is projected to record 2.7% CAGR and reach US$2 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Gonadotropin & Gonadotropin Releasing Hormones Therapy segment is readjusted to a revised 3.2% CAGR for the next 7-year period.



The U.S. Market is Estimated at $830.8 Million, While China is Forecast to Grow at 2.8% CAGR

The Male Hypogonadism market in the U.S. is estimated at US$830.8 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$618.1 Million by the year 2027 trailing a CAGR of 2.8% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2.7% and 2.4% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 3% CAGR.

Select Competitors (Total 47 Featured):
  • AbbVie, Inc.
  • Allergan PLC
  • AstraZeneca PLC
  • Bayer AG
  • Eli Lilly and Company
  • Endo International PLC
  • Ferring International Center SA
  • IBSA Institut Biochimique SA
  • Laboratoires Genevrier
  • Merck & Co., Inc.
  • Teva Pharmaceutical Industries Ltd.
Note: Product cover images may vary from those shown
I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Current & Future Analysis for Male Hypogonadism by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 2: World Historic Review for Male Hypogonadism by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 3: World 15-Year Perspective for Male Hypogonadism by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027
  • Table 4: World Current & Future Analysis for Testosterone Replacement Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 5: World Historic Review for Testosterone Replacement Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 6: World 15-Year Perspective for Testosterone Replacement Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
  • Table 7: World Current & Future Analysis for Gonadotropin & Gonadotropin Releasing Hormones Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 8: World Historic Review for Gonadotropin & Gonadotropin Releasing Hormones Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 9: World 15-Year Perspective for Gonadotropin & Gonadotropin Releasing Hormones Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
  • Table 10: World Current & Future Analysis for Topical Gels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 11: World Historic Review for Topical Gels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 12: World 15-Year Perspective for Topical Gels by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
  • Table 13: World Current & Future Analysis for Injectables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 14: World Historic Review for Injectables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 15: World 15-Year Perspective for Injectables by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
  • Table 16: World Current & Future Analysis for Transdermal Patches by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 17: World Historic Review for Transdermal Patches by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 18: World 15-Year Perspective for Transdermal Patches by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
  • Table 19: World Current & Future Analysis for Other Drug Deliveries by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 20: World Historic Review for Other Drug Deliveries by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 21: World 15-Year Perspective for Other Drug Deliveries by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
III. MARKET ANALYSIS
  • UNITED STATES
  • Table 22: USA Current & Future Analysis for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 23: USA Historic Review for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 24: USA 15-Year Perspective for Male Hypogonadism by Therapy - Percentage Breakdown of Value Sales for Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy for the Years 2012, 2020 & 2027
  • Table 25: USA Current & Future Analysis for Male Hypogonadism by Drug Delivery - Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 26: USA Historic Review for Male Hypogonadism by Drug Delivery - Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 27: USA 15-Year Perspective for Male Hypogonadism by Drug Delivery - Percentage Breakdown of Value Sales for Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries for the Years 2012, 2020 & 2027
  • CANADA
  • Table 28: Canada Current & Future Analysis for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 29: Canada Historic Review for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 30: Canada 15-Year Perspective for Male Hypogonadism by Therapy - Percentage Breakdown of Value Sales for Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy for the Years 2012, 2020 & 2027
  • Table 31: Canada Current & Future Analysis for Male Hypogonadism by Drug Delivery - Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 32: Canada Historic Review for Male Hypogonadism by Drug Delivery - Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 33: Canada 15-Year Perspective for Male Hypogonadism by Drug Delivery - Percentage Breakdown of Value Sales for Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries for the Years 2012, 2020 & 2027
  • JAPAN
  • Table 34: Japan Current & Future Analysis for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 35: Japan Historic Review for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 36: Japan 15-Year Perspective for Male Hypogonadism by Therapy - Percentage Breakdown of Value Sales for Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy for the Years 2012, 2020 & 2027
  • Table 37: Japan Current & Future Analysis for Male Hypogonadism by Drug Delivery - Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 38: Japan Historic Review for Male Hypogonadism by Drug Delivery - Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 39: Japan 15-Year Perspective for Male Hypogonadism by Drug Delivery - Percentage Breakdown of Value Sales for Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries for the Years 2012, 2020 & 2027
  • CHINA
  • Table 40: China Current & Future Analysis for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 41: China Historic Review for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 42: China 15-Year Perspective for Male Hypogonadism by Therapy - Percentage Breakdown of Value Sales for Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy for the Years 2012, 2020 & 2027
  • Table 43: China Current & Future Analysis for Male Hypogonadism by Drug Delivery - Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 44: China Historic Review for Male Hypogonadism by Drug Delivery - Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 45: China 15-Year Perspective for Male Hypogonadism by Drug Delivery - Percentage Breakdown of Value Sales for Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries for the Years 2012, 2020 & 2027
  • EUROPE
  • Table 46: Europe Current & Future Analysis for Male Hypogonadism by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 47: Europe Historic Review for Male Hypogonadism by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 48: Europe 15-Year Perspective for Male Hypogonadism by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027
  • Table 49: Europe Current & Future Analysis for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 50: Europe Historic Review for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 51: Europe 15-Year Perspective for Male Hypogonadism by Therapy - Percentage Breakdown of Value Sales for Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy for the Years 2012, 2020 & 2027
  • Table 52: Europe Current & Future Analysis for Male Hypogonadism by Drug Delivery - Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 53: Europe Historic Review for Male Hypogonadism by Drug Delivery - Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 54: Europe 15-Year Perspective for Male Hypogonadism by Drug Delivery - Percentage Breakdown of Value Sales for Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries for the Years 2012, 2020 & 2027
  • FRANCE
  • Table 55: France Current & Future Analysis for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 56: France Historic Review for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 57: France 15-Year Perspective for Male Hypogonadism by Therapy - Percentage Breakdown of Value Sales for Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy for the Years 2012, 2020 & 2027
  • Table 58: France Current & Future Analysis for Male Hypogonadism by Drug Delivery - Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 59: France Historic Review for Male Hypogonadism by Drug Delivery - Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 60: France 15-Year Perspective for Male Hypogonadism by Drug Delivery - Percentage Breakdown of Value Sales for Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries for the Years 2012, 2020 & 2027
  • GERMANY
  • Table 61: Germany Current & Future Analysis for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 62: Germany Historic Review for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 63: Germany 15-Year Perspective for Male Hypogonadism by Therapy - Percentage Breakdown of Value Sales for Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy for the Years 2012, 2020 & 2027
  • Table 64: Germany Current & Future Analysis for Male Hypogonadism by Drug Delivery - Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 65: Germany Historic Review for Male Hypogonadism by Drug Delivery - Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 66: Germany 15-Year Perspective for Male Hypogonadism by Drug Delivery - Percentage Breakdown of Value Sales for Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries for the Years 2012, 2020 & 2027
  • ITALY
  • Table 67: Italy Current & Future Analysis for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 68: Italy Historic Review for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 69: Italy 15-Year Perspective for Male Hypogonadism by Therapy - Percentage Breakdown of Value Sales for Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy for the Years 2012, 2020 & 2027
  • Table 70: Italy Current & Future Analysis for Male Hypogonadism by Drug Delivery - Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 71: Italy Historic Review for Male Hypogonadism by Drug Delivery - Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 72: Italy 15-Year Perspective for Male Hypogonadism by Drug Delivery - Percentage Breakdown of Value Sales for Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries for the Years 2012, 2020 & 2027
  • UNITED KINGDOM
  • Table 73: UK Current & Future Analysis for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 74: UK Historic Review for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 75: UK 15-Year Perspective for Male Hypogonadism by Therapy - Percentage Breakdown of Value Sales for Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy for the Years 2012, 2020 & 2027
  • Table 76: UK Current & Future Analysis for Male Hypogonadism by Drug Delivery - Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 77: UK Historic Review for Male Hypogonadism by Drug Delivery - Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 78: UK 15-Year Perspective for Male Hypogonadism by Drug Delivery - Percentage Breakdown of Value Sales for Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries for the Years 2012, 2020 & 2027
  • REST OF EUROPE
  • Table 79: Rest of Europe Current & Future Analysis for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 80: Rest of Europe Historic Review for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 81: Rest of Europe 15-Year Perspective for Male Hypogonadism by Therapy - Percentage Breakdown of Value Sales for Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy for the Years 2012, 2020 & 2027
  • Table 82: Rest of Europe Current & Future Analysis for Male Hypogonadism by Drug Delivery - Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 83: Rest of Europe Historic Review for Male Hypogonadism by Drug Delivery - Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 84: Rest of Europe 15-Year Perspective for Male Hypogonadism by Drug Delivery - Percentage Breakdown of Value Sales for Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries for the Years 2012, 2020 & 2027
  • ASIA-PACIFIC
  • Table 85: Asia-Pacific Current & Future Analysis for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 86: Asia-Pacific Historic Review for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 87: Asia-Pacific 15-Year Perspective for Male Hypogonadism by Therapy - Percentage Breakdown of Value Sales for Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy for the Years 2012, 2020 & 2027
  • Table 88: Asia-Pacific Current & Future Analysis for Male Hypogonadism by Drug Delivery - Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 89: Asia-Pacific Historic Review for Male Hypogonadism by Drug Delivery - Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 90: Asia-Pacific 15-Year Perspective for Male Hypogonadism by Drug Delivery - Percentage Breakdown of Value Sales for Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries for the Years 2012, 2020 & 2027
  • REST OF WORLD
  • Table 91: Rest of World Current & Future Analysis for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 92: Rest of World Historic Review for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 93: Rest of World 15-Year Perspective for Male Hypogonadism by Therapy - Percentage Breakdown of Value Sales for Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy for the Years 2012, 2020 & 2027
  • Table 94: Rest of World Current & Future Analysis for Male Hypogonadism by Drug Delivery - Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 95: Rest of World Historic Review for Male Hypogonadism by Drug Delivery - Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 96: Rest of World 15-Year Perspective for Male Hypogonadism by Drug Delivery - Percentage Breakdown of Value Sales for Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries for the Years 2012, 2020 & 2027
IV. COMPETITION
  • Total Companies Profiled: 47
Note: Product cover images may vary from those shown
Adroll
adroll